Pluristem Therapeutics makes appointment
This article was originally published in Scrip
Pluristem Therapeutics, a US biotherapeutics company commercialising non-personalised cell therapy products for the treatment of several degenerative, ischaemic and autoimmune disorders, has named Chaya Mazouz clinical operations director. Ms Mazouz previously served as clinical operations director for the biopharmaceutical company Medgenics.
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.